ATM-Mediated Translocation of RanBPM Regulates DNA Damage Response by Stabilizing p21 in Non-Small Cell Lung Cancer Cells

doi:10.21203/rs.3.rs-2946638/v1

Download PDF

Research Article

ATM-Mediated Translocation of RanBPM Regulates DNA Damage Response by Stabilizing p21 in Non-Small Cell Lung Cancer Cells

https://doi.org/10.21203/rs.3.rs-2946638/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 07 Sep, 2023

Read the published version in Cellular Oncology →

You are reading this latest preprint version

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-induced deaths around the world, and platinum-based chemotherapy remains a standard-of-care for most patients with advanced NSCLC. DNA damage response (DDR) induced by platinum or Etoposide activated a panel of cell cycle-regulatory proteins including p21 through p53 pathway. In this present study, we found that the level of p21 or RanBPM is lower in NSCLC than non-malignant tissues and has a highly positive correlation, which is positively correlated with the survival of patients. We further revealed that RanBPM protein physically interacts with p21, RanBPM deubiquitinates p21 by recruiting a deubiquitinase USP11 to maintain protein stability of p21. Furthermore, RanBPM regulates DNA damage response (DDR) in a p21-dependent manner, and DNA damage promotes the translocation of RanBPM into the nucleus and regulates p21 protein stability through ATM-mediated pathways. We revealed a novel mechanism of p21 protein stability regulated by RanBPM, and the novel roles of RanBPM in the regulation of DDR.

RanBPM

p21

deubiquitination

USP11

DNA damage

Lung cancer is a frequently diagnosed malignancy with the second morbidity and the highest mortality worldwide. According to the latest Global Cancer Statistics 2020, lung cancer accounts for 11.4% of the total new cases, and for 18% of the total cancer deaths¹. Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for 80–85% of all cases². Based on the histological features, NSCLC is further divided into lung adenocarcinomas, squamous cell carcinoma and large cell carcinoma³. Platinum-based chemotherapy is the standard-of-care for NSCLC patients before or after surgery, or alongside radiotherapy, or for the advanced NSCLC patients⁴. Chemotherapy-caused DNA damage activates a series of DNA damage response (DDR), including the activation of ATM/ATR, and then triggers the downstream cell processes, such as cell cycle arrest, DNA damage repair, cell senescence or apoptosis⁵. However, cancer cells will develop drug-resistance after a period of treatment. Therefore, it is urgently required to reveal the molecular mechanism of drug resistance of NSCLC, identify the predictive diagnostic biomarkers, and develop the new therapies.

RanBPM, known as RanBP9, is a ubiquitous, evolutionarly conserved scaffold protein, which is localized in both cytoplasm and nucleus⁶. Previous studies have demonstrated that RanBPM interacts with multiple proteins that involved in various cellular processes, such as cell adhesion and migration, DDR and signal transduction^7–9. RanBPM-deficient mice show early perinatal lethality and sterility^10,11. RanBPM has also been identified as a critical regulator of protein stabilization, and regulates diverse biological functions through protein interaction. RanBPM sustains the protein stabilization of Mgl-1, and promotes its tumor suppressor activity¹². However, the detailed mechanism underlying the effect of RanBPM on DDR of NSCLC cells remains unclear.

As a broadly acting cyclin-dependent kinase inhibitor, p21 plays a critical roles of tumor suppressor. The dysregulation of p21 has been reported in multiple human cancers ¹³. In normal physiological conditions, p21 protein is rapidly degraded by the ubiquitin-proteasome pathway ^14,15. However, in response to diverse cellular stress, such as DNA damage, the protein levels of p21 rapidly elevated, which results in cell cycle arrest, apoptosis or cellular senescence¹⁶. Recent studies have revealed that USP11 deubiquitinates and stabilizes p21 protein under physiological conditions, as well as in response to DNA damage¹⁷.

In this present study, we reported a new molecular mechanism by which RanBPM sustains the protein stability of p21 in a USP11-dependent manner. In particular, we found that DNA damage promoted the ATM-mediated nuclear translocation of RanBPM protein, and colocalized and physically interacted with p21. Taken together, RanBPM has been identified as a novel regulator of p21 protein stability, and plays a critical role in the regulation of DDR.

Cell Cultures. HEK293T, A549 and H1299 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA). A549 and H1299 cells were cultured in RPMI 1640 medium (Gibco, ThermoFisher Scientific, Friendship, ME, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA) plus 5 mM glutamine, penicillin G (100 U mL^− 1) and streptomycin (100 µg mL^− 1) at 37°C under 5% CO₂. HEK293T were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin. The experiment protocol was approved by the Ethics Committee of the Guangdong Pharmaceutical University.

Antibodies and chemicals. Specific antibodies against p53 (DO-1, sc-126), p15 (D-12, sc-271791), p19 (SPM429, sc-65594) and RanBPM (sc-271727) antibodies were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA), and p18 (#2896), p21 (#2947), p57 (#2557) and RanBPM (#14638) antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-p16 (A301-267A) was purchased from Bethyl Laboratories (Montgomery, TX, USA). Anti-p27 (AF1669), anti-ATM (AF1399) and anti-phospho-ATM (Ser1981) were purchased from Beyotime Biotechnology (Shanghai, China). Anti-USP11 (ab109232) and anti-RanBPM (ab205954) antibodies were purchased from Abcam (Shanghai, China). Anti-GAPDH (AT0002) antibodies were purchased from CMCTAG (Milwaukee, WI, USA). Anti-Flag (cat. M185-3L), anti-Myc (cat. M192-3) and anti-HA (cat. M180-3) antibodies were purchased from Medical ༆ Biological Laboratories CO., LTD. (Minato-ku, Tokyo, Japan). Etoposide (VP-16, S1225) and KU-55933 (S1092) were purchased from Selleck Chemicals (Shanghai, China), and Cycloheximide (sc-3508B) and MG132 (C2211) were purchased from Sigma (Shanghai, China). Doxorubicin (SC0159) was purchased from Beyotime Biotechnology (Shanghai, China).

Western Blotting and Immunoprecipitation. The procedures of western blotting and Immunoprecipitation assay were performed as previously described¹⁷.

GST Pulldown Assays. GST fusion proteins and His fusion proteins were produced following standard protocol. For in vitro binding assays, bacterially expressed GST-p21 bound to glutathione Sepharose beads (Thermo Scientific, 16100) were incubated with His-RanBPM. After washing, the bound proteins were separated by SDS-PAGE and immunoblotted with indicated antibodies.

Protein Half-Life Assays. Cells were transfected with the indicated siRNA for 48 h, or transfected with specified plasmids for 24 h followed by treatment with/without cycloheximide (50 µg·mL^− 1) for various periods of time, washed with PBS, and lysed in RIPA buffer containing a protease inhibitor cocktail. The protein levels were assessed using Western blot analysis.

Real-time PCR. Total RNA was extracted using Trizol (Takara Bio, Otsu, Japan). RNA (1 µg) was reverse-transcribed in a 20 µL reaction using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, #K1622). After reverse transcription at 42℃ for 60 min, then 42℃ for 15 min and inactivation by incubating samples at 70℃ for 5 min, the RT reaction was diluted. cDNA was used for RT-PCR or real-time PCR assay. Primer sequences were as follows:

RanBPM-F: GGTGATGTCATTGGCTGTTG

RanBPM-R: AATTTGGCGGTAGGTCAGTG

GAPDH-F: AAGGTGAAGGTCGGAGTCAA

GAPDH-R: AATGAAGGGGTCATTGATGG

p21-F: ATTAGCAGCGGAACAAGGAGTCAGACAT

p21-R: CTGTGAAAGACACAGAACAGTACAGGGT

RNA interference. The sequences of the RanBPM siRNAs have been previously reported:

siUSP11#1: 5’-AAUGAGAAUCAGAUCGAGUCC-3’

siUSP11#2: 5’-AAGGCAGCCUAUGUCCUCUUC-3’

siRanBPM#1: 5’- GGCCACACAAUGUCUAGGA-3’,

siRanBPM#2: 5’-GGAAUUGGAUCCUGCGCAU-3’, and the sequence of the control siRNA is 5’-UUCUCCGAACGUGUCACGUUUC-3’. All these siRNAs were synthesized by Shanghai GenePharma. siRNA transfection was performed in cells using GeneMut siRNA transfection reagent (SignaGen Laboratories cat. SL100568) (Rockville, MD, USA). The experimental procedure followed the protocol provided by the manufacturers.

In vivo ubiquitylation assay. HEK293T cells were transfected with the indicated siRNAs, or transfected with the indicated plasmids for 24 h followed by treatment with 20 µM MG132 for 6 h, washed with PBS, and lysed in RIPA buffer containing a protease inhibitor cocktail. The lysates were transferred into a 1.5 mL tube and placed on a hot plate immediately to boil for 10 min. Then the lysates were incubated with anti-His antibody overnight, followed by treatment with protein A/G beads for an additional 2 h at 4℃. After three washes with PBS buffer containing 1‰ Tween-20 (PBST), ubiquitinated p21 was analyzed using immunoblotting with anti-HA antibody.

Clonogenic survival assay. Cells were treated with the indicated drugs, then collected, counted, diluted, then finally seeded into 6-well plate at an appropriate density for each treatment. After 10 to 14 days of incubation, the colonies were fixed and stained with crystal violet for 30 minutes. The colonies (≥ 0.3mm) with at least 50 cells were counted as survivors under a stereomicroscope by ImageJ software. Data are representative of three independent experiments.

Immunohistochemical staining analysis. Formalin-fixed, paraffin-embedded samples were sectioned at 5 µM. Sections were treated with antigen retrieval buffer. Specifically, incubation with antibodies against RanBPM (1:50 dilution; Santa Cruz, USA), p21 (1:100 dilution; CST) was carried out overnight at room temperature. Slides were incubated in secondary antibody. The protein levels of RanBPM and p21 in the tumor specimens from NSCLC patients were reviewed and scored under a light microscope. Each specimen was quantified and assigned a score based on the intensity of the membrane, cytoplasmic, and/or nucleic staining by a visual grading system (0–3) (grade 0, no staining; grade 1, weak staining; grade 2, moderate staining, grade 3, strong staining) and the extent of stained cells (0% =0, 1–24% =1, 25–49% =2, 50–74%=3, 75–100%=4). The final immunoreactive score ranges from 0 (no staining) to 12 (strong staining).

Survival analysis. The effects of RanBPM genes on the survival of patients with NSCLC were analysed using Kaplan–Meier Plotter (http://kmplot.com/analysis/)¹⁸, which contained gene expression data and survival information of 2,434 clinical NSCLC patients.

Statistical analysis.

All data were analyzed by GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA; RRID:SCR_002798) or FlowJo software (FlowJo, RRID:SCR_008520). Results are presented as mean ± SEM or mean ± SD as indicated. The statistical difference between two samples was analyzed by Students t test. One-way ANOVA was used to analyze the statistical difference of multiple groups. *P < 0.05 and **P < 0.01. P < 0.05 was considered as statistically significant.

RanBPM is positively correlated with p21, and correlated with the survival of NSCLC patients. To explore the roles of RanBPM in the development of NSCLC, we performed immunohistochemical (IHC) staining using antibodies against RanBPM on a tumor tissue microarray consisting of 52 NSCLC patient specimens. NSCLC tumor specimens express much lower RanBPM levels than the normal tissues adjacent to the tumor (Fig. 1A-B). It was reported that RanBPM knockdown induced cell cycle arrest at S-phase ⁹. However, the detailed mechanism remains unclear. We analyzed the correlation of RanBPM (RANBP9) with cyclin-dependent kinases inhibitors (CKIs) by using Gene Expression Profiling Interactive Analysis (GEPIA) web server (Fig. 1D and Figure S1A). The expression levels of RanBPM is positively correlated with p21(CDKN1A) in NSCLC tumor samples (Fig. 1C). RanBPM knockdown specifically decreased p21 level (Figure S1B). We further validated the correlation of RanBPM with p21 protein levels in NSCLC tumor specimens by IHC analysis (Fig. 1D-E). These data indicated that the expression of RanBPM is positively correlated with p21 in the tumor specimens of NSCLC patients.

RanBPM protein interacts with p21. RanBPM, as a scaffolding protein, is a crucial component of multiple-protein complex that mediate diverse cellular functions by modulating and/or assembling with various kinds of proteins¹⁹. Given RanBPM is positively correlated with p21, we further tested whether RanBPM protein physically interacts with p21. RanBPM or p21 was separately immunoprecipitated from the lysates of A549 cells, and the protein of p21 or RanBPM was detected by western blotting. As shown in Fig. 2A and B, both RanBPM and p21 were detected in their individual immunoprecipitated complexes, but not in the isotype-matched negative control IgG complexes. We also detected the colocalization of RanBPM and p21 proteins in the nucleus (Fig. 2C). Furthermore, the plasmids encoding Flag-RanBPM or Myc-p21 were transfected into HEK293T cells, and RanBPM or p21 protein was co-immunoprecipitated (co-IP) with an anti-Flag or anti-Myc antibody. The exogenously expressed RanBPM was pulled down by the ectopically-overexpressed p21, while the exogenously expressed p21 was pulled down by the ectopically-overexpressed RanBPM as well (Fig. 2D-E). To further validate whether RanBPM physically interacts with p21 protein, we performed GST-pull down assay by using the purified recombinant His-RanBPM and GST-p21 proteins. The GST-p21, but not the GST control, was able to pull down the His-RanBPM protein under cell-free conditions (Fig. 2F), demonstrating a direct protein interaction between RanBPM and p21. Collectively, these results suggested that RanBPM physically interacts with p21 protein in vivo and in vitro.

RanBPM stabilizes and deubiquitinates p21 protein. Since RanBPM protein physically interacts with p21, we next investigated whether RanBPM affects the steady-state levels of p21 protein. As shown in Fig. 3A, knockdown of RanBPM with two independent RanBPM specific short interfering RNAs (siRNAs) significantly decreased p21 level in A549 and H1299 cells. Conversely, RanBPM overexpression led to the accumulation of endogenous p21 protein regardless of the p53 status (Figs. 3B). To determine whether RanBPM regulates p21 at the level of gene transcription, we measured the mRNA levels of p21 gene by qRT-PCR after RanBPM downregulation or overexpression. RanBPM did not significantly change the levels of p21 mRNA (Fig. 3C-D). The data suggested that RanBPM regulates the post-translational modifications, rather than gene transcription of p21 gene.

To further elucidate the mechanism by which RanBPM sustains the protein stability of p21, we monitored the protein degradation of p21 when the cells were treated with proteasome inhibitor MG132. In the absence of MG132, RanBPM overexpression or downregulation elevated or declined p21 protein levels in A549 or H1299 cells, while dysregulation of p21 caused by RanBPM could be blocked by the proteasome inhibitor MG132 (Fig. 3E-F). The data demonstrated that RanBPM regulates p21 protein by ubiquitin-proteasome pathway. Furthermore, when the protein biosynthesis was inhibited with cycloheximide (CHX), the knockdown of endogenous RanBPM decreased the half-life of the p21 protein (Fig. 3G and H), while RanBPM overexpression profoundly extended the half-life of the p21 protein (Fig. 3I). To further validate the underlying mechanism by which RanBPM regulates the stability of p21, we measured the levels of polyubiquitination of p21 protein by co-transfecting the plasmids encoding Myc-p21 and HA-Ubiquitin to HEK293T cells. RanBPM overexpression reduced the levels of polyubiquitylated p21 (Fig. 3J), whereas RanBPM knockdown significantly increased the levels of p21 polyubiquitylation (Fig. 3K).

RanBPM facilitates p21 deubiquitination in a USP11-dependent manner. It has well known that USP11 plays a key role in the maintenance of p21 protein stability¹⁷. Interestingly, USP11 recently was identified as a potential binding partner for RanBPM protein ²⁰. We validated the protein interaction with sequential immunoprecipitation assays. The plasmids encoding Flag-RanBPM, HA-USP11 and Myc-p21 were co-transfected to HEK293T cells, and RanBPM protein was first immunoprecipitated with anti-Flag M2 agarose beads and eluted with Flag peptides. p21 proteins were secondly immunoprecipitated with anti-Myc antibody. The data showed that the USP11 was detected in both immunoprecipitates obtained with anti-Flag or anti-Myc antibodies (Fig. 4A). These data indicated that RanBPM, p21 and USP11 were present in the same protein complex.

We further presumed that RanBPM might promote interaction between USP11 and p21, and regulate USP11-dependent deubiquitination of p21. We tested the impact of RanBPM on the protein interaction of USP11 with p21. The ectopic overexpression of RanBPM promoted the protein interaction between USP11 and p21, whereas RanBPM knockdown with siRNAs significantly reduced the USP11-p21 interactions (Fig. 4B-C). Furthermore, sub-cellular localization of p21 and USP11 were further detected by immunofluorescent staining after RanBPM was knocked down in A549 cells. The knockdown of RanBPM did not seem to change the sub-cellular localization of p21 and USP11 (Figures S2).

Because RanBPM affected the interaction of USP11 with p21, we hypothesized that RanBPM is involved in USP11-mediated regulation of p21. To address this, Flag-USP11 was transfected into RanBPM-knockdown cells. As expected, the effect of USP11 on p21 markedly decreased after RanBPM knockdown (Fig. 4D). Ectopical overexpression of RanBPM dramatically promoted, whereas RanBPM knockdown decreased USP11-mediated p21 deubiquitination (Fig. 4E-F). These results suggest that RanBPM plays a vital role in USP11-mediated regulation of p21.

As well known, RanBPM is a scaffold protein without any enzymatic activity¹⁹, we deduced that RanBPM sustains p21 protein stability depending on the deubiquitinase activity of USP11. USP11 knockdown significantly reduced the protein levels of p21, which has been reported in a previous study¹⁷. We further clarified whether RanBPM facilitates p21 deubiquitination in a USP11-dependent manner. As shown in Fig. 4G and 4H, USP11 knockdown impaired RanBPM-sustained p21 protein stability and the deubiquitination level. These results indicated that RanBPM stabilizes and deubiquitinates p21 protein by promoting the binding of USP11 to p21.

RanBPM regulates DNA damage response in a p21-dependent manner. A549 and H1299 cells with RanBPM knockdown showed a lower ATM activation and defective homology-directed repair (HDR), and DNA damage induced more cell apoptosis ^9,21. To demonstrate the crucial roles of RanBPM in DDR, we measured the cell proliferation and clonogenic formation in response to genotoxic stress using CCK-8 assays. The data indicated that RanBPM knockdown with siRNAs increased the sensitivity of A549 to genotoxic stress (Fig. 5A-C). The rescue of exogenous p21 in the RanBPM-depleted cells fully reversed the effect of RanBPM ablation (Fig. 5D-G). These data suggested that the RanBPM-mediated DDR is dependent on p21.

DNA damage promotes the translocation of RanBPM into the nucleus and regulates p21 protein stability. It was reported that p21 regulates DNA damage response (DDR) by p53-dependent or independent pathways^22,23, Since RanBPM stabilizes and deubiquitinates p21 protein, we next investigated whether DNA damage elevates p21 protein levels through RanBPM-mediated pathways. In agreement with previous reports²⁴, etoposide elevated p21 protein levels in A549 and H1299 cells (Fig. 6A and B), while etoposide-elevated p21 protein levels significantly decreased in the RanBPM-depleted cells (Fig. 6A). Furthermore, RanBPM knockdown significantly decreased the doxorubicin-triggered p21 elevation (Fig. 6B), but had no impact on the mRNA levels of p21 gene (Fig. 6C and D). These results suggested that RanBPM regulates DNA damage-elevated p21 protein.

Since p21 acts as a tumor suppressor in the nucleus, we hypothesized RanBPM might translocate into the nucleus to participate in DDR. We performed cell fractionation assays or immunofluorescence to confirm the hypothesis. As shown in Fig. 6E, DNA damage significantly elevated the amounts of RanBPM in the nucleus. In addition, DNA damage promoted the translocalization of RanBPM proteins to the nucleus (Fig. 6F).

Furthermore, we analyzed the physical protein interaction of RanBPM with p21. A549 cells were treated with etoposide or doxorubicin, and cell lysates were subjected to co-immunoprecipitation with anti-RanBPM or anti-p21 antibody. DNA damage significantly promoted the protein interaction between RanBPM and p21 (Fig. 6G and H). These data suggested that RanBPM is indispensable for the p21 protein stability in physiological conditions, or elevated protein levels in response to DNA damage (Fig. 6I).

DNA damage promotes the translocation of RanBPM and regulates p21 protein stability through ATM-mediated pathways. DDR induced posttranslational modifications of proteins such as phosphorylation, which are crucial for controlling protein stability, localization and activity²⁵. The DDR signaling pathway orchestrated by the ATM and ATR kinases is the central regulator of this network in response to DNA damage²⁶. ATM has been reported as a binding partner of RanBPM²¹. We speculated DNA damage induced p21 protein accumulation through ATM-mediated translocation of RanBPM. Firstly, etoposide or doxorubicin up-regulated p21 protein levels in A549 and H1299 cells. However, the elevated p21 protein was remarkably decreased by ATM inhibitor Ku55933 (Fig. 7A-B). We performed cell fractionation assays to monitor the translocation of RanBPM protein. As shown in Fig. 7C, DNA damage significantly increased the amounts of RanBPM proteins in the nucleus. Intriguingly, ATM inhibition by Ku55933 reversed DNA damage-induced nuclear translocation of RanBPM. The data were validated by immunofluorescence (Fig. 7D-E). These results suggested that DNA damage significantly promoted the nuclear translocation of RanBPM protein through ATM-dependent pathways.

RanBPM as a ubiquitous protein localizes in both the nucleus and cytoplasm, and has emerged as a scaffolding protein to regulate the functions of multiple binding partners by protein-protein interaction. Several studies have reported the vital roles of RanBPM in the regulation of DDR. In the present study, we reported that RanBPM sustains p21 protein stability by tethering a deubiquitinase USP11 to p21, and inhibiting p21 ubiquitination and degradation. Additionally, we also reported that RanBPM is required for DNA damage-induced p21 protein elevation, while the knockdown of RanBPM increases the sensitization of NSCLC cells to DNA damaging agents in a p21-dependent manner (Fig. 5E and 5G). Under normal physiological conditions, RanBPM localizes in both the cell nucleus and cytoplasm, while DNA damage promotes the nuclear translocation of RanBPM proteins in a ATM-dependent manner, thereby promoting the interaction of USP11 with p21, and stabilizing p21 protein. These results increased our understanding on the novel roles of RanBPM in the DNA damage elevates p21 protein stability, which is independent of p53 pathway.

p21 is an unstable protein with a relatively short half-life, while the intrinsic and extrinsic stresses such as DNA damage or DNA replication stress rapidly elevated the protein level. The elevation of p21 protein mainly is regulated by post-translational modifications such as phosphorylation or ubiquitylation. Three E3 ubiquitin ligase complexes, SCF^Skp2, CRL4^Cdt2, and APC/C^Cdc20, have been reported to trigger p21 ubiquitylation and degradation at specific stages of the cell cycle. Previous study has reported that USP11 levels varies with cell cycles, and inhibits the ubiquitylation and proteasomal degradation of p21 in a cell-cycle–independent manner. Further studies are needed to fully reveal the detailed mechanism by which RanBPM regulates p21 during cell cycle.

Altogether, the present studies demonstrated that RanBPM plays a crucial role in the USP11-p21 regulatory loop when NSCLC cells were treated by DNA damage agents. DNA damage promotes the nuclear translocation of RanBPM protein, and promotes p21 protein stabilization by facilitating the interaction of p21 with a deubiquitinase USP11 (Fig. 8). The project revealed a novel mechanism by which RanBPM regulates p21 protein stability, and plays a critical role in the regulation of DDR, thereby suggesting that it might be a promising therapeutic strategy to develop small compounds destroying the protein interaction between RanBPM and p21.

Author contributions

DTG, XL: data collection and analysis, project development. DTG, CXF, XYG, ZZB, PYC, YLL, FYM: data collection and analysis. DTG and XL: manuscript writing. LX: Writing- Reviewing and Editing. All authors read and approved the final manuscript.

Funding

This study was funded by the National Natural Science Foundation of China (NSFC 82103422), Guangdong Basic and Applied Basic Research Foundation (2021A1515011053), Guangzhou Science and Technology Plan Project (202102020153), National Key Specialty Construction Project of Clinical Pharmacy, High Level Clinical Key Specialty of Clinical Pharmacy in Guangdong Province.

Data availability

All material and data presented in the manuscript are available.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Competing interests The authors declare that they have no competing interests.

H. Sung, J. Ferlay, R.L. Siegel et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209–249
Z. Chen, C.M. Fillmore, P.S. Hammerman, C.F. Kim, K.K. Wong, Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer. 14(8), 535–546 (2014)
A. Thomas, S.V. Liu, D.S. Subramaniam, G. Giaccone, Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12(9), 511–526 (2015)
A. Rossi, Di M. Maio, Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev. Anticancer Ther. 16(6), 653–660 (2016)
D. Woods, J.J. Turchi, Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol. Ther. 14(5), 379–389 (2013)
M. Nakamura, H. Masuda, J. Horii et al., When overexpressed, a novel centrosomal protein, RanBPM, causes ectopic microtubule nucleation similar to gamma-tubulin. J. Cell Biol. 143(4), 1041–1052 (1998)
S. Kramer, T. Ozaki, K. Miyazaki, C. Kato, T. Hanamoto, A. Nakagawara, Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells. Oncogene. 24(5), 938–944 (2005)
J.A. Woo, S.E. Roh, M.K. Lakshmana, D.E. Kang, Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 26(4), 1672–1681 (2012)
A. Tessari, K. Parbhoo, M. Pawlikowski et al., RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene. 37(50), 6463–6476 (2018)
J.P. Palavicini, B.N. Lloyd, C.D. Hayes et al., RanBP9 Plays a Critical Role in Neonatal Brain Development in Mice. PloS one. 8(6), e66908 (2013)
S. Puverel, C. Barrick, S. Dolci, V. Coppola, L. Tessarollo, RanBPM is essential for mouse spermatogenesis and oogenesis. Development. 138(12), 2511–2521 (2011)
B. Suresh, S. Ramakrishna, Y.S. Kim, S.M. Kim, M.S. Kim, K.H. Baek, Stability and function of mammalian lethal giant larvae-1 oncoprotein are regulated by the scaffolding protein RanBPM. J. Biol. Chem. 285(46), 35340–35349 (2010)
T. Abbas, A. Dutta, p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9(6), 400–414 (2009)
N.A. Warfel, W.S. El-Deiry, p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 25(1), 52–58 (2013)
Z. Lu, T. Hunter, Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell. cycle. 9(12), 2342–2352 (2010)
A. Karimian, Y. Ahmadi, B. Yousefi, Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA repair. 42, 63–71 (2016)
T. Deng, G. Yan, X. Song et al., Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses. Proc. Natl. Acad. Sci. U S A 115(18), 4678–4683 (2018)
B. Gyorffy, P. Surowiak, J. Budczies, A. Lanczky, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PloS one. 8(12), e82241 (2013)
S. Das, B. Suresh, H.H. Kim, S. Ramakrishna, RanBPM: a potential therapeutic target for modulating diverse physiological disorders. Drug discovery today. 22(12), 1816–1824 (2017)
H. Ideguchi, A. Ueda, M. Tanaka et al., Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM. Biochem. J. 367(Pt 1), 87–95 (2002)
D. Palmieri, M. Scarpa, A. Tessari et al., Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. Oncotarget. 7(14), 18371–18383 (2016)
K.F. Macleod, N. Sherry, G. Hannon et al., p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9(8), 935–944 (1995)
T. Abbas, A. Dutta, p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9(6), 400–414 (2009)
H. Ding, W. Duan, W.G. Zhu et al., P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem. Biophys. Res. Commun. 305(4), 950–956 (2003)
M.S. Huen, J. Chen, The DNA damage response pathways: at the crossroad of protein modifications. Cell Res. 18(1), 8–16 (2008)
A. Marechal, L. Zou, DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 2013;5(9)

No competing interests reported.

Download PDF

Journal Publication

published 07 Sep, 2023

Read the published version in Cellular Oncology →

Editorial decision: Major revision
14 Jun, 2023
Reviews received at journal
05 Jun, 2023
Reviewers agreed at journal
01 Jun, 2023
Reviewers agreed at journal
31 May, 2023
Reviewers agreed at journal
31 May, 2023
Reviewers invited by journal
31 May, 2023
Editor assigned by journal
22 May, 2023
Submission checks completed at journal
22 May, 2023
First submitted to journal
17 May, 2023

You are reading this latest preprint version

ATM-Mediated Translocation of RanBPM Regulates DNA Damage Response by Stabilizing p21 in Non-Small Cell Lung Cancer Cells

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Materials and Methods

Statistical analysis.

Results

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1